Eyal Lebel

Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis

Shlomit Kfir‐Erenfeld, Nathalie Asherie, Sigal Grisariu et al. · Clinical Cancer Research · 2022 · 36 citations

Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial

Nathalie Asherie, Shlomit Kfir‐Erenfeld, Batia Avni et al. · Haematologica · 2022 · 26 citations · Full text

Hematological Malignancy, Car T Cells, Radiation Oncology +14

Venetoclax in Relapse/Refractory AL Amyloidosis—A Multicenter International Retrospective Real-World Study

Eyal Lebel, Efstathios Kastritis, Giovanni Palladini et al. · Cancers · 2023 · 24 citations · Full text

Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study

Chava Perry, Sharon Ben Barouch, Neta Goldschmidt et al. · American Journal of Hematology · 2019 · 21 citations

Early lymphocyte collection for <scp>anti‐CD19 CART</scp> production improves T‐cell fitness in patients with relapsed/refractory diffuse large B‐cell lymphoma

Tatyana Dubnikov Sharon, Miri Assayag, Batia Avni et al. · British Journal of Haematology · 2023 · 20 citations · Full text